India Unlimited: ICPA event in San Diego on 2nd June to discuss drug discovery scenario in India

New Delhi: International Contract Pharma Association (ICPA) will be organizing an event focused on drug discovery scenario in India on 2nd June in San Deigo, USA.

Titled ‘India Unlimited’ the event themed Collaborate, Invest, Outsource will happen on the sidelines of the world largest biotechnology event, BIO International Convention

The opening address will be delivered by Dr Anil Chauhan, Founder Director, ICPA who will delve into the key opportunity areas and vast untapped potential within drug discovery and CDMO space in India.

The first session at the event will focus on India’s growing global footprint and prowess in biologics. The session will host Dr Cyrus Karkaria, President, Biotechnology – Lupin; Dr Mandakini Goel, Associate Director, Business Strategy Solution Consulting, Clarivate; Tuhin Bhowmick, CEO & Director, Pandorum Technologies.

The panelists will share the successes and lessons from their efforts and on why India provides an attractive investment destination for Biologics development, manufacture, and export. The role of government support in growing the innovation ecosystem and scale-up of manufacturing will also be discussed.

The second session is focused on Servicing Global Research, Discovery, Development and Manufacturing requirements of international companies. Besides the increased demand, a high and consistent service quality is an important driver.

The session will witness presence of Dr Jitendra Kumar, Managing Director, Biotechnology Industry Research Assistance Council (BIRAC); Joseph Damond, Chair, Global Life Sciences, C&M International (CMI); Russell Miller, Vice President, Global Sales and Marketing-CDMO business., Enzene Biosciences; Alex Del Priore, Senior Vice President – Manufacturing, Syngene International; and Dr Roger Lias, Global Commercial Head – NBE, Aurigene International.

Panelist will share their perspective on how international stakeholders can benefit from outsourcing their requirements to India.
Dr Anil Chauhan, Founder Director, ICPA commented: “India is doing well in the biotech area and aspires to be a USD 150 billion bioeconomy. India is in the forefront with its Vaccines development and Drug manufacturing and has now started exporting biosimilars. With leading companies, its contract services business has picked up pace.”

“Through the India Unlimited meeting on June 2, ICPA would like Indian companies and its public sector organizations to engage with various international stakeholders in a collective manner to explain the opportunities in India. It is quite well known that the cost of developing a new drug is in the range of 1.5 billion USD. India provides excellent facilities and companies to partner for all stages of drug development and manufacturing. This will reduce the development costs and also get new drugs to the market faster. The meeting is aimed to facilitate collaborations with and investments & out-sourcing to India,” added Dr Chauhan.

The event that presents a network opportunity with key 100 stakeholders is supported by BIRAC, Enzene Bioscience, Clarivate, C&M International, Aurigene, and Syngene.

Those interested to attend the event can register here

Speaking about his experiences at BIO, Dr Chauhan says: “I have been attending the annual BIO International Convention for the past 17 years and have never ceased to be amazed at the number and quality of attendees from around the globe. BIO 2024 San Diego will provide an exceptional opportunity no matter what stage a company or organization is at. One could be a start-up, a Multi-billion MNC, an EDO, an academic or public organization, Investor or a Country delegation member.”

Source: https://biovoicenews.com